Furthermore, Fröhlich et al. recently discussed the second-generation MAPK Adaptive Resistance Model (MARM2.0), which aims to explain how drug-adapted BRAFV600E melanoma cells rewire EGFR/MAPK signalling. The gene discussed is EGFR; the disease is melanoma.